TScan is dedicated to creating life-changing T cell therapies for patients by unleashing the untapped potential of the human immune system. TScan Therapeutics was founded in 2018 by a small group of scientists led by Dr. Stephen Elledge (Harvard Medical School/HHMI). TScan is discovering and developing novel TCR-engineered T cell therapies for the treatment of cancer. Our discovery platform is centered around a breakthrough technology that enables the rapid, comprehensive, and genome-wide identification of the peptide antigen targets of T cell receptors. This technology greatly enhances our ability to understand the specific antigens that drive important disease processes, including tumor cell recognition by the immune system, self-reactivity in autoimmune disorders, and acquired immunity in infectious disease. TScan is using the platform in oncology to discover new TCR/target pairs and to rapidly move novel TCRs into clinical development.
Location: United States, Massachusetts, Waltham
Employees: 51-200
Total raised: $183M
Founded date: 2018
Investors 4
| Date | Name | Website |
| - | K2 HealthV... | k2healthve... |
| - | 6 Dimensio... | 6dimension... |
| - | RA Capital... | racap.com |
| - | GV | gv.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 25.01.2021 | Series C | $100M | - |
| 09.01.2020 | Series B | $35M | - |
| 24.07.2019 | Series B | $48M | - |
Mentions in press and media 8
| Date | Title | Description | Source |
| 06.03.2024 | TScan Therapeutics Reports Fourth Quarter and Full Year 2023... | - | globenewsw... |
| 05.01.2023 | TScan Therapeutics Announces 2023 Clinical Plans and Highlig... | Phase 1 umbrella trial of TSC-100 and TSC-101 active in five sites; on track to enroll first two coh... | einpresswi... |
| 13.12.2021 | TScan Therapeutics Announces Poster Presentations at the 63r... | - Posters highlight discovery of TSC-101, manufacturing process and clinical development plan for li... | marketscre... |
| 19.08.2021 | TScan Therapeutics Reports Second Quarter 2021 Financial Res... | Debuted as Publicly Traded Company and Raised $100 Million in Gross Proceeds to Fund Liquid and Soli... | marketscre... |
| 25.01.2021 | TScan Therapeutics Raises $100M in Series C Financing | TScan Therapeutics, a Waltham, Mass.-based biopharmaceutical company focused on the development of T... | finsmes.co... |
| 09.01.2020 | TScan Therapeutics Completes $35M Series B Funding | TScan Therapeutics, a Waltham, Mass.-based company dedicated to creating life-changing T cell therap... | finsmes.co... |
| 24.07.2019 | TScan Therapeutics Raises Series B Financing; $48M To Date | TScan Therapeutics, a Boston, MA-based company that designs therapies that reprogram a patient’s own... | finsmes.co... |
| - | TScan Therapeutics | “Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien velit, aliquet eget commodo... | fastfounde... |